{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-006461","form_type":"8-K","ticker":"SRTS","cik":"0001494891","company_name":"Sensus Healthcare, Inc.","filed_at":"2022-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.717841+00:00","generated_at":"2026-06-27T09:10:18.623094+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensus Healthcare Q4 record revenue $13.0M, EPS $0.32; FY 2021 revenue $27.0M up 182%","bullets":["Q4 revenue $13.0M (+156% YoY); net income $5.3M ($0.32 diluted EPS) vs $1.0M ($0.06) in Q4 2020.","Full-year 2021 revenue $27.0M (+182%); diluted EPS $0.25 vs loss of $0.42 in 2020.","Shipped record 35 systems in Q4, including 3 to China; received Ministry of Health license renewal through 2026.","Signed exclusive U.S. distribution agreement for TransDermal Infusion System for needle-less drug delivery.","Affirms expectation for Q1 2022 continued growth and full-year 2022 profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-006461","json":"https://secwatch.observer/filing/0001213900-22-006461.json","markdown":"https://secwatch.observer/filing/0001213900-22-006461.md","text":"https://secwatch.observer/filing/0001213900-22-006461.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1494891/000121390022006461/0001213900-22-006461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1494891/000121390022006461/ea155130-8k_sensus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:10:18.623094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}